BACKGROUND: C-Reactive protein (CRP) has been shown to play a pivotal role in the pathogenesis of atherosclerosis progression. The aim of this study was to assess whether CRP predicts severity, progression, and prognosis of aortic valve stenosis (AS). METHODS: One hundred and thirty-five patients with asymptomatic AS were studied. Patients were diagnosed as mild (n = 18, aortic valve area [AVA] > or =1.5 cm(2)), moderate (n = 57, AVA 1.0-1.49 cm(2)), or severe AS (n = 60, AVA <1.0 cm(2)) by Doppler echocardiography. Patients with serial (baseline and at 1 year) echocardiographic examination (n = 47) were grouped as either slow (n = 22, DeltaAVA <-0.15 cm(2)/y) or rapid progression group (n = 25, DeltaAVA > or =-0.15 cm(2)/y). In addition, long-term prognosis was compared between patients with low CRP (n = 68, CRP <0.15 mg/dL) and those with high CRP (n = 67, CRP > or =0.15 mg/dL). RESULTS: Baseline CRP was significantly higher in patients with severe AS than in those with mild or moderate AS (mild AS 0.17 +/- 0.43, moderate AS 0.22 +/- 0.28, severe AS 0.53 +/- 0.66 mg/dL, P = .001). By multivariate logistic regression analysis, CRP was an independent predictor of severe AS (odds ratio 3.51, P = .015). Similarly, CRP was significantly higher in the rapid progression group than in the slow progression group (0.56 +/- 0.76 vs 0.19 +/- 0.25 mg/dL, P = .004). Furthermore, long-term survival was significantly lower in the high CRP group than in the low CRP group (log rank: P < .001). CONCLUSION: C-Reactive protein predicts severity, progression, and prognosis in patients with asymptomatic AS.
BACKGROUND:C-Reactive protein (CRP) has been shown to play a pivotal role in the pathogenesis of atherosclerosis progression. The aim of this study was to assess whether CRP predicts severity, progression, and prognosis of aortic valve stenosis (AS). METHODS: One hundred and thirty-five patients with asymptomatic AS were studied. Patients were diagnosed as mild (n = 18, aortic valve area [AVA] > or =1.5 cm(2)), moderate (n = 57, AVA 1.0-1.49 cm(2)), or severe AS (n = 60, AVA <1.0 cm(2)) by Doppler echocardiography. Patients with serial (baseline and at 1 year) echocardiographic examination (n = 47) were grouped as either slow (n = 22, DeltaAVA <-0.15 cm(2)/y) or rapid progression group (n = 25, DeltaAVA > or =-0.15 cm(2)/y). In addition, long-term prognosis was compared between patients with low CRP (n = 68, CRP <0.15 mg/dL) and those with high CRP (n = 67, CRP > or =0.15 mg/dL). RESULTS: Baseline CRP was significantly higher in patients with severe AS than in those with mild or moderate AS (mild AS 0.17 +/- 0.43, moderate AS 0.22 +/- 0.28, severe AS 0.53 +/- 0.66 mg/dL, P = .001). By multivariate logistic regression analysis, CRP was an independent predictor of severe AS (odds ratio 3.51, P = .015). Similarly, CRP was significantly higher in the rapid progression group than in the slow progression group (0.56 +/- 0.76 vs 0.19 +/- 0.25 mg/dL, P = .004). Furthermore, long-term survival was significantly lower in the high CRP group than in the low CRP group (log rank: P < .001). CONCLUSION:C-Reactive protein predicts severity, progression, and prognosis in patients with asymptomatic AS.
Authors: William M Yarbrough; Rupak Mukherjee; John S Ikonomidis; Michael R Zile; Francis G Spinale Journal: J Thorac Cardiovasc Surg Date: 2011-07-16 Impact factor: 5.209
Authors: Neil Ruparelia; Vasileios F Panoulas; Angela Frame; Ben Ariff; Nilesh Sutaria; Michael Fertleman; Jonathan Cousins; Jon Anderson; Colin Bicknell; Andrew Chukwuemeka; Sayan Sen; Iqbal S Malik; Antonio Colombo; Ghada W Mikhail Journal: World J Cardiol Date: 2016-07-26
Authors: Jesse D Rogers; Brian A Aguado; Kelsey M Watts; Kristi S Anseth; William J Richardson Journal: Proc Natl Acad Sci U S A Date: 2022-02-22 Impact factor: 12.779
Authors: Serkan Kahraman; Arda Can Dogan; Gokhan Demirci; Ali Riza Demir; Emre Yilmaz; Hicaz Zencirkiran Agus; Ali Kemal Kalkan; Fatih Uzun; Mehmet Erturk Journal: Braz J Cardiovasc Surg Date: 2020-06-01
Authors: Anders Holmgren; Johan Ljungberg; Johan Hultdin; Bengt Johansson; Ingvar A Bergdahl; Ulf Näslund; Stefan Söderberg Journal: Open Heart Date: 2020-10